Since the approval of the first lipid nanoparticle (LNP)–assisted siRNA therapeutics (patisiran) for the treatment of hATTR amyloidosis, three other siRNA therapeutics that are chemically modified with N-acetylgalactosamine (GalNAc) have been successfully developed for hepatocyte-targeting delivery by specifically binding with asialoglycoprotein receptor (ASGPR) on the cell surface (51). This evidence concerns the gene ASGR1 and amyloidosis.